Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Importance of monitoring and early switch to second generation tyrosine kinase inhibitors for the prognosis of patients with chronic myeloid leukemia with imatinib resistance or intolerance
Author: SIMÕES, Belinda Pinto
BRAGA JUNIOR, José Wilson Ramos
REGO, Maria Aparecida do Carmo
SOUZA, Cármino Antônio de
Abstract: Imatinib mesylate was the first BCR-ABL-target agent approved for the treatment of chronic myeloid leukemia. Although most patients respond well to imatinib therapy, the literature shows that one third develops resistance or intolerance. The timing of second-line treatment after failure of initial treatment may have a significant impact on long-term outcome. Thus, appropriate monitoring to identify resistance and/or intolerance is crucial to early intervention with second generation tyrosine kinase inhibitors and attainment of better results
Subject: Leukemia, myelogenous, chronic, BCR-ABL positive - drug therapy
Drug resistance
Drug monitoring, neoplasm
Receptor Protein-Tyrosine Kinases
Pyrimidines - therapeutic use
Antineoplastic agents - administration & dosage
Country: Brasil
Editor: Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea
Citation: Revista Brasileira de Hematologia e Hemoterapia, v.33, n.1, p.65-72, 2011
Rights: aberto
Identifier DOI: 10.5581/1516-8484.20110017
Date Issue: 2011
Appears in Collections:HEMO - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
art_SIMOES_Importance_of_monitoring_and_early_switch_to_2011.pdf325.33 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.